• News

"HIMC At Mount Sinai To Evaluate Therapeutic Effects Of Novel Cancer Immunotherapy"

  • News-Medical
  • New York, NY
  • (November 05, 2019)

The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi. Led by Miriam Merad, MD, PhD, director of the precision immunology institute and co-director of cancer immunology program, The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai, the HIMC leverages new proprietary technologies and platforms to characterize immune profiles and responses across a diverse range of disease settings. “We are a team of highly integrated scientists with distinct expertise in medicine, immunology, technology, mathematics and physics, whose goals are to dissect the contribution of the immune system to human diseases and use this knowledge to design novel immune-based therapies," said Dr. Merad. "The breadth and number of partnerships between the HIMC and leading academic and industry partners reflects the quality of cutting-edge, proprietary techniques and technologies developed by Dr. Merad and her team," said Erik Lium, PhD, executive vice president of Mount Sinai Innovation Partners.

— Miriam Merad, MD, PhD, Professor, Medicine, Hematology and Medical Oncology, Oncological Sciences, Director, Precision Immunology Institute, Director, Mount Sinai Human Immune Monitoring Center, Co-Director, Cancer Immunology Program, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

— Erik Lium, PhD, Executive Vice President, Mount Sinai Innovation Partners

Learn more 

Additional coverage: Health News Digest